On March 19, HCmed Innovations announced that its medical nebulizer, Pulmogine, has successfully been shipped to the U.S. market. The device will be used in combination with dornase alfa (Pulmozyme), a biologic developed by Genentech, a member of the Roche Group, for the treatment of patients with cystic fibrosis.

Pulmogine is HCmed’s first portable, continuous-use medical nebulizer. Dornase alfa remains the only inhaled biologic currently approved on the global market. During treatment, patients can inhale aerosolized dornase alfa particles, measuring 3 to 5 micrometers, through normal breathing. The medication reduces the viscosity of mucus in the lungs, helping cystic fibrosis patients expel mucus more easily and lowering the risk of airway infections. This combination product received U.S. FDA approval in February of last year.

Chieh-Sheng Cheng, Chairman of HCmed Innovations, stated that entering the U.S. market and combining Pulmogine with Genentech’s dornase alfa for the treatment of cystic fibrosis patients marks a major milestone for the company in the development and manufacturing services (CDMO) of inhalation nebulizer devices. HCmed has already established partnerships with local collaborators in the U.S. to jointly promote Pulmogine, and it will continue investing resources to expand sales and provide comprehensive after-sales service in the American market.

Resource: 心誠鎂 進軍美國市場